Investor Planning to Hold This Stock (DVA, OPK, FSLR, AKAM)

Los Angelas, CA -- (SBWIRE) -- 01/11/2013 -- DaVita HealthCare Partners Inc. (NYSE:DVA) and a leading provider of kidney care services, today announced an agreement to provide certain pharmacy services to Fresenius Medical Care (FMC).FMC, a leading provider of dialysis services and maker of dialysis products, will use DaVita Rx® prescription drug services for its Medicare patients in the United States. Congress required that beginning in 2011, some oral medications will be included in the bundled payment model. By 2016 all oral end stage renal disease medications will be included in the bundled payment. FMC’s contract with DaVita Rx will help implement that requirement by using DaVita Rx’s state-of–the-art pharmacy to fill and ship oral medications to FMC Medicare patients. DaVita Rx service for FMC will begin in late 2013.

Is DVA Going To Move Higher As Many Investors Expect: Find Out Here

Opko Health (NYSE:OPK) signed a deal to acquire Canadian drug company Cytochroma, which has two products in Phase 3 clinical trials, for $100 million. The Miami-based pharmaceutical and biotechnology company (NYSE: OPK) would issue shares of its stock as compensation for the deal, its second acquisition in the past two months after buying a pharmaceutical company in Brazil in December. Both of Cytochroma’s products involve patients with kidney problems. Replidea is a vitamin D prohormone to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease in addition to vitamin D insufficiency. More than eight million patients have stage 3 or 4 chronic kidney disease, according to the National Kidney Foundation. About 70 to 90 percent of such patients have vitamin D insufficiency and 40 to 60 percent of them have SHPT.

Is OPK will continue moving higher? Find out where OPK is headed next with a FREE TREND ANALYSIS REPORT

First Solar, Inc. (NASDAQ:FSLR) today announced the appointment of Tim Rebhorn as Senior Vice President, Project Development. He reports to First Solar CEO Jim Hughes and will be responsible for the company's global project development strategy and execution. "Tim will play a crucial role in implementing First Solar's strategy to provide fully integrated photovoltaic power solutions in sustainable markets around the world," said Jim Hughes . "He brings proven strengths in business development, mergers and acquisitions, integration, value creation and strategy implementation."

How Should Investors Trade BGNN After The Recent Momentum, Find Out Here

Akamai Technologies (NASDAQ:AKAM) also says volumes about AT&T. This partnership will give AT&T a good gateway into the lucrative Content Data Network (CDN) segment. Unlike the Internet, which is typical of congestion, CDN services avert congestion, making them very popular among enterprises. This partnership, which is primarily focused on online businesses within North America, brightens prospects for AT&T. For starters, AT&T has a strong footprint in the North American market and as such, the partnership is likely to attract a lot of customers; especially considering that Akamai will deploy CDN servers at the edge of AT&T’s IP network. Secondly and arguably most importantly, online business is set to grow at a rate bordering on what could be described as exponential.

Should Investors Wait For Rally On AKAM OR EXIT From Here? CLICK HERE To Know More

Disclaimer
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com